Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

ImmunoGen Narrows Fiscal 1Q Loss to $11.2M

By Pharmaceutical Processing | October 25, 2013

ImmunoGen cut its fiscal first quarter loss in half and raised its expectations for the year, as the cancer drug developer brought in more milestone and royalty payments from other pharmaceutical companies.

The Waltham, Mass., company’s shares rose 5 percent Friday before markets opened.

ImmunoGen booked $7.8 million in license fees from drugmaker Eli Lilly and Co. in the quarter. It also received a $5 million milestone payment and $2.1 million in royalties from Swiss drug developer Roche after Japanese regulators approved the breast cancer treatment Kadcyla, which uses ImmunoGen technology.

The company lost $11.2 million, or 13 cents per share, in the quarter that ended Sept. 30. That compares to a loss of $25.2 million, or 30 cents per share, in last year’s quarter. Revenue jumped to $17.2 million from $4.1 million.

Analysts expected, on average, a loss of 22 cents per share on $12.2 million in revenue, according to FactSet.

ImmunoGen Inc. now expects a net loss of between $67 million and $71 million for the year on revenue of $71 million to $75 million. That compares to its previous forecast for a loss ranging from $72 million to $76 million on $66 million to $70 million in revenue.

The company’s shares climbed 83 cents to $18.08 in premarket trading. The stock had already climbed more than 35 percent so far this year, as of Thursday’s close.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE